keyword
MENU ▼
Read by QxMD icon Read
search

muscle invasive urothelial bladder cancer

keyword
https://www.readbyqxmd.com/read/28218662/microrna-expression-profile-identifies-high-grade-non-muscle-invasive-bladder-tumors-at-elevated-risk-to-progress-to-an-invasive-phenotype
#1
Sara M Lenherr, Sheaumei Tsai, Brasil Silva Neto, Travis B Sullivan, Cara B Cimmino, Tanya Logvinenko, Jason Gee, Wei Huang, John A Libertino, Ian C Summerhayes, Kimberly M Rieger-Christ
The objective of this study was to identify a panel of microRNAs (miRNAs) differentially expressed in high-grade non-muscle invasive (NMI; TaG3-T1G3) urothelial carcinoma that progress to muscle-invasive disease compared to those that remain non-muscle invasive, whether recurrence happens or not. Eighty-nine high-grade NMI urothelial carcinoma lesions were identified and total RNA was extracted from paraffin-embedded tissue. Patients were categorized as either having a non-muscle invasive lesion with no evidence of progression over a 3-year period or as having a similar lesion showing progression to muscle invasion over the same period...
February 17, 2017: Genes
https://www.readbyqxmd.com/read/28210516/immunohistochemical-investigation-of-her-akt-mtor-pathway-and-cellular-adhesion-molecules-in-urothelial-carcinomas
#2
Nikolaos Koletsas, Triantafyllia Koletsa, Spyros Choidas, Konstantinos Anagnostopoulos, Stavros Touloupidis, Thomas Zaramboukas, Georgia Raptou, Nikolaos Papadopoulos, Maria Lambropoulou
Background. Several investigators have suggested the possibility that the expression of both EGFR and HER2 could be utilized for molecularly targeted therapy in urinary bladder cancer. We tried to evaluate the expression of HER2 and EGFR and activation of the AKT/PTEN/mTOR pathway in urothelial carcinomas and if there is any association between them and cellular adhesion molecules (CAMs). Materials and Methods. Forty-one paraffin-embedded urothelial cancer tissue blocks were collected. Immunostains for HER2, EGFR, MIB1, phospho-AKT, PTEN, phospho-mTOR, e-cadherin, p-cadherin, and b-catenin were performed on tissue microarrays sections...
2017: Pathology Research International
https://www.readbyqxmd.com/read/28197393/preclinical-efficacy-and-safety-of-the-ty21a-vaccine-strain-for-intravesical-immunotherapy-of-non-muscle-invasive-bladder-cancer
#3
Sonia Domingos-Pereira, Valérie Cesson, Mathieu F Chevalier, Laurent Derré, Patrice Jichlinski, Denise Nardelli-Haefliger
Intravesical Bacillus-Calmette-Guérin (BCG) immunotherapy can reduce recurrence/progression of non-muscle-invasive bladder cancer (NMIBC), although significant adverse events and treatment failure argue for alternative options. Here, we examined whether another attenuated live vaccine, Vivotif/Ty21a, used since more than 30 y against typhoid fever, may be safely used intravesically to improve bladder-tumor treatment. Mice-bearing MB49 orthotopic bladder-tumors treated with intravesical Ty21a or BCG were compared for survival and bacteria recovery...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28195647/molecular-classification-of-urothelial-carcinoma-global-mrna-classification-versus-tumour-cell-phenotype-classification
#4
Gottfrid Sjödahl, Pontus Eriksson, Fredrik Liedberg, Mattias Höglund
Global mRNA expression analysis is efficient for phenotypic profiling of tumours and has been used to define molecular subtypes for almost every major tumour type. A key limitation is that most tumours are communities of both tumour and non-tumour cells. This problem is particularly pertinent when analysing advanced invasive tumours, known to induce major changes and responses in both the tumour and the surrounding tissue. To identify bladder cancer tumour-cell phenotypes and compare classification by tumour-cell phenotype with classification by global gene expression analysis, we analysed 307 advanced bladder cancers (cystectomised) both by genome gene expression analysis and by immunohistochemistry using antibodies for 28 proteins...
February 13, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28163086/long-term-survival-outcomes-with-intravesical-nanoparticle-albumin-bound-paclitaxel-for-recurrent-nonmuscle-invasive-bladder-cancer-after-previous-bacillus-calmette-gu%C3%A3-rin-therapy
#5
Dennis J Robins, Wilson Sui, Justin T Matulay, Rashed Ghandour, Christopher B Anderson, G Joel DeCastro, James M McKiernan, John K Lattimer
OBJECTIVE: To report long-term follow up results of a phase II trial of salvage intravesical nanoparticle albumin bound (nab)-paclitaxel for patients with recurrent non-muscle invasive bladder cancer after previous intravesical Bacillus Calmette-Guérin (BCG) therapy. METHODS: This was a phase II trial investigating the use of intravesical nab-paclitaxel in patients with recurrent Tis, Ta, and T1 urothelial carcinoma who failed at least one prior induction course of intravesical BCG...
February 2, 2017: Urology
https://www.readbyqxmd.com/read/28134806/systemic-immunotherapy-for-urothelial-cancer-current-trends-and-future-directions
#6
REVIEW
Shilpa Gupta, David Gill, Austin Poole, Neeraj Agarwal
Urothelial cancer of the bladder, renal pelvis, ureter, and other urinary organs is the fifth most common cancer in the United States, and systemic platinum-based chemotherapy remains the standard of care for first-line treatment of advanced/metastatic urothelial carcinoma (UC). Until recently, there were very limited options for patients who are refractory to chemotherapy, or do not tolerate chemotherapy due to toxicities and overall outcomes have remained very poor. While the role of immunotherapy was first established in non-muscle invasive bladder cancer in the 1970s, no systemic immunotherapy was approved for advanced disease until the recent approval of a programmed death ligand-1 (PD-L1) inhibitor, atezolizumab, in patients with advanced/metastatic UC who have progressed on platinum-containing regimens...
January 27, 2017: Cancers
https://www.readbyqxmd.com/read/28122346/setd6-regulates-nf-%C3%AE%C2%BAb-signaling-in-urothelial-cell-survival-implications-for-bladder-cancer
#7
Neelam Mukherjee, Eduardo Cardenas, Roble Bedolla, Rita Ghosh
Non-muscle invasive bladder cancer has a high recurrence rate of 45-70%, progressing to muscle invasive disease in about 15% of those patients over a 5-year period. Administration of the mycobacterium, Bacillus Calmette-Guerin (BCG) that induces local inflammation resulting in tumor remission in responsive patients is frequently used for treatment. BCG-treated patients with NF-κB del/del genotype have an increased risk of recurrence suggesting an important role of NF-κB in bladder cancer. Since protein methyltransferases play critical roles in modulating chromatin structure and gene expression, we screened a focused array of epigenetic modification genes to identify differential expression between normal urothelial and bladder cancer cells...
January 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28113097/the-immune-infiltrate-in-prostate-bladder-and-testicular-tumors-an-old-friend-for-new-challenges
#8
REVIEW
Cinzia Solinas, Nieves Martinez Chanzá, Ahmad Awada, Mario Scartozzi
In genito-urinary tumors immunotherapy has been administered for a long time: Calmette-Guèrin Bacillus as adjuvant treatment in high risk patients with non muscle invasive urothelial bladder cancer and interleukin-2 and interferon-α in metastatic kidney cancer. The vaccine Sipuleucel-T has been approved by United States Food and Drug Administration for the treatment of castration resistant prostate cancer patients with asymptomatic or minimally symptomatic disease, given the 22% reduction of mortality risk in this group...
February 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28106542/urinary-nid2-and-twist1-methylation-to-augment-conventional-urine-cytology-for-the-detection-of-bladder-cancer
#9
Joseph J Fantony, Thomas A Longo, Ajay Gopalakrishna, Richmond Owusu, Raymond S Lance, Wen-Chi Foo, Brant A Inman, Michael R Abern
BACKGROUND: Abnormal methylation of urinary TWIST1 and NID2 conferred high sensitivity and specificity for the detection of urothelial carcinoma. OBJECTIVE: We examine the performance of the urine-based TWIST1/NID2 methylation assay with the addition of urine cytology for the detection of urothelial carcinoma. MATERIALS AND METHODS: A prospective multi-institutional study was conducted to assess the performance of a methylation assay for patients with hematuria or under surveillance for non-muscle invasive bladder cancer (NMIBC)...
January 13, 2017: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/28101348/evans-blue-mediated-white-light-detection-of-non-muscle-invasive-bladder-cancer-a-preclinical-feasibility-and-safety-study-using-a-rat-bladder-urothelial-cell-carcinoma-model
#10
Sanne Elsen, Evelyne Lerut, Frank Van Der Aa, Ben Van Cleynenbreugel, Hendrik Van Poppel, Peter De Witte
Photodynamic diagnosis (PDD) improves the detection of non-muscle-invasive bladder cancer (NMIBC). However, white-light (WL) cystoscopy remains the technique routinely used in urological clinics. A more cost-effective but equally performant alternative to PDD may encompass the use of an intense tumoritropic dye in combination with WL cystoscopy. Using a preclinical setting, we investigated the practical aspects of the use of Evans blue (EB) dye for the possible future detection of NMIBC using WL cystoscopy...
December 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28064545/androgen-receptor-activation-a-prospective-therapeutic-target-for-bladder-cancer
#11
Taichi Mizushima, Kathleen A Tirador, Hiroshi Miyamoto
Patients with non-muscle-invasive or muscle-invasive bladder cancer undergoing surgery and currently available conventional therapy remain having a high risk of tumor recurrence or progression, respectively. Novel targeted molecular therapy is therefore expected to improve patient outcomes. Meanwhile, substantially higher incidence of bladder cancer in men has prompted research on androgen-mediated androgen receptor (AR) signaling in this malignancy. Indeed, preclinical evidence has suggested that AR signaling plays an important role in urothelial carcinogenesis and tumor outgrowth as well as resistance to some of the currently available conventional non-surgical therapies...
January 19, 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28043166/pharmacokinetic-drug-evaluation-of-atezolizumab-for-the-treatment-of-locally-advanced-or-metastatic-urothelial-carcinoma
#12
REVIEW
Rutveej Patel, Megan Bock, Charles F Polotti, Sammy Elsamra
Muscle invasive bladder cancer (MIBC) is difficult to manage for patients who progress during or after initial chemotherapy regimens. Current regimens offer low response rates with high toxicities. The advent of immune checkpoint inhibitors may represent a new opportunity for effective management of these patients. Areas covered: Atezolizumab is an engineered humanized monoclonal immunoglobulin G1 antibody that binds selectively to PD-L1 and prevents its interaction with PD-1 and B7-1. It is administered intravenously and is given every 3 weeks as long as there is no evidence of tumor progression...
February 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28040351/clinical-outcomes-of-patients-with-histologic-variants-of-urothelial-cancer-treated-with-trimodality-bladder-sparing-therapy
#13
Ross E Krasnow, Michael Drumm, Hannah J Roberts, Andrzej Niemierko, Chin-Lee Wu, Shulin Wu, Jing Zhang, Niall M Heney, Matthew F Wszolek, Michael L Blute, Adam S Feldman, Richard J Lee, Anthony L Zietman, William U Shipley, Jason A Efstathiou
BACKGROUND: Trimodality bladder-sparing therapy (TMT) is an acceptable treatment for selected patients with muscle-invasive urothelial cancer. Outcomes of TMT in histologic variants remains largely unknown. OBJECTIVE: To compare outcomes of pure urothelial carcinoma (PUC) to variant urothelial carcinoma (VUC) after TMT. DESIGN, SETTING, AND PARTICIPANTS: Retrospective study of patients treated with TMT at a single cancer center from 1993 until 2013...
December 28, 2016: European Urology
https://www.readbyqxmd.com/read/28035618/who-1973-grade-3-and-infiltrative-growth-pattern-proved-aberrant-e-cadherin-expression-tends-to-be-of-predictive-value-for-progression-in-a-series-of-stage-t1-high-grade-bladder-cancer-after-organ-sparing-approach
#14
Wolfgang Otto, Johannes Breyer, Sonja Herdegen, Fabian Eder, Simone Bertz, Matthias May, Roman Mayr, Eva M Lausenmeyer, Stefan Denzinger, Bas W G van Rhijn, Maximilian Burger, Arndt Hartmann
PURPOSE: Stage pT1 urothelial bladder cancer (UBC) is characterized as a challenging subentity of urothelial carcinoma with an unforeseeable clinical course. In addition to more or less established clinical and histopathological features, we evaluated the role of epithelial-mesenchymal transition (EMT) marker E-cadherin, shown to be of prognostic value in muscle-invasive disease, regarding the prognosis of stage pT1 high-grade (hg) UBC. METHODS: Tissue of 226 stage pT1 hg UBC patients from transurethral resection could be immunostained for E-cadherin...
December 29, 2016: International Urology and Nephrology
https://www.readbyqxmd.com/read/28035325/effect-of-neoadjuvant-chemotherapy-on-renal-function-following-radical-cystectomy-is-there-a%C3%A2-meaningful-impact
#15
Thenappan Chandrasekar, Neil Pugashetti, Blythe Durbin-Johnson, Marc A Dall'Era, Christopher P Evans, Ralph W deVere White, Stanley A Yap
Objective: To evaluate the patterns of impact of neoadjuvant chemotherapy (NAC) on renal function across the initial year following treatment for muscle-invasive bladder cancer (MIBC) with radical cystectomy (RC). Methods: We reviewed the charts of 241 patients who underwent RC for urothelial carcinoma of the bladder between 2003-14 at our institution. Renal function was evaluated at multiple time points (pre-chemotherapy, pre-operatively, post-operatively, 6-12 months follow-up), and then classified by CKD staging...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28035322/micropapillary-bladder-cancer-insights-from-the-national-cancer-database
#16
Wilson Sui, Justin T Matulay, Maxwell B James, Ifeanyi C Onyeji, Marissa C Theofanides, Arindam RoyChoudhury, G Joel DeCastro, Sven Wenske
Introduction: Micropapillary bladder cancer (MPBC) is a variant histology of urothelial carcinoma (UC) that is associated with poor outcomes however given its rarity, little is known outside of institutional reports. We sought to use a population-level cancer database to assess survival outcomes in patients treated with surgery, radiation therapy and/or chemotherapy. Materials and Methods: The National Cancer Database (NCDB) was queried for all cases of MPBC and UC using International Classification of Disease-O-3 morphologic codes between 2004-2014...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28035321/patterns-of-bladder-preservation-therapy%C3%A2-utilization-for-muscle-invasive-bladder-cancer
#17
Tracy L Rose, Allison M Deal, Sylvain Ladoire, Gilles Créhange, Matthew D Galsky, Jonathan E Rosenberg, Joaquim Bellmunt, Akhila Wimalasingham, Yu-Ning Wong, Lauren C Harshman, Simon Chowdhury, Guenter Niegisch, Michalis Liontos, Evan Y Yu, Sumanta K Pal, Ronald C Chen, Andrew Z Wang, Matthew E Nielsen, Angela B Smith, Matthew I Milowsky
Background: Trimodality bladder preservation therapy (BPT) in muscle invasive bladder cancer (MIBC) includes a maximal transurethral resection followed by concurrent chemoradiotherapy as an alternative to radical cystectomy (RC) in appropriately selected patients, or as a treatment option in non-cystectomy candidates. Several chemotherapy regimens can be used in BPT, but little is known about current practice patterns. Objective: To describe utilization patterns of BPT and associated survival outcomes in MIBC...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28013415/prognostic-impact-of-preoperative-anemia-on-non-muscle-invasive-bladder-carcinoma-treated-with-greenlight-laser-vaporization
#18
Fei Luo, Ya-Shen Wang, Yan-Hui Su, Zhi-Hua Zhang, Hong-Hong Sun, Jian Li
In this study, we aimed to evaluate the impact of preoperative anemia (PA) on oncological outcomes among patients with non-muscle-invasive bladder cancer (NMIBC) treated with GreenLight laser vaporization of bladder tumor (PV-BT). Between January 2010 and December 2015, 407 patients with NMIBC who underwent PV-BT surgery were stratified into normal and anemia groups based on the World Health Organization classification (anemia cutoff value: hemoglobin level, <13.0 m g/dL in men and <12.0 mg/dL in women)...
February 2017: Lasers in Medical Science
https://www.readbyqxmd.com/read/28004470/carbonic-anhydrase-2-is-a-novel-invasion-associated-factor-in-urinary-bladder-cancers
#19
Hirokazu Tachibana, Min Gi, Minoru Kato, Shotaro Yamano, Masaki Fujioka, Anna Kakehashi, Yukiyoshi Hirayama, Yuki Koyama, Satoshi Tamada, Tatsuya Nakatani, Hideki Wanibuchi
Rat bladder cancer is nearly always papillary non-invasive urothelial carcinoma (UC). To establish an animal model mimicking invasive UC that arises from papillary non-invasive UC in the bladder, male human c-Ha-ras proto-oncogene transgenic rats (Hras128) were treated with 0.05% N-butyl-N-(hydroxybutyl)nitrosameine (BBN) in their drinking water and/or 0.1% phenylethyl isothiocyanate (PEITC) in their diet as follows: BBN (8 weeks)→PEITC (8 weeks); PEITC (8 weeks)→BBN (8 weeks); BBN alone (16 weeks); PEITC alone (16 weeks); no-treatment...
December 22, 2016: Cancer Science
https://www.readbyqxmd.com/read/27980085/the-feasibility-and-effectiveness-of-robot-assisted-radical-cystectomy-after-neoadjuvant-chemotherapy-in-patients-with-muscle-invasive-bladder-cancer
#20
Takuya Koie, Chikara Ohyama, Hayato Yamamoto, Atsushi Imai, Shingo Hatakeyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Tohru Yoneyama, Yuki Tobisawa, Atsushi Yamauchi, Toru Shimazui, Mikinobu Ohtani
OBJECTIVES: The aim of this study was to compare 29 muscle-invasive bladder cancer patients who received neoadjuvant chemotherapy (NAC) followed by immediate robot-assisted radical cystectomy (RARC) with those who underwent minimum-incision endoscopic RC (MIE-RC). METHODS: We retrospectively reviewed the charts of 430 consecutive patients who underwent RC and bilateral pelvic node dissection (PLND) between May 1994 and July 2016. Our study focused on patients with MIBC who had histologically confirmed stage T2-T4aN0M0 urothelial carcinoma of the bladder and received NAC prior to surgery...
December 15, 2016: Japanese Journal of Clinical Oncology
keyword
keyword
105932
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"